PMID- 25197377
OWN - NLM
STAT- MEDLINE
DCOM- 20150609
LR  - 20240507
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 7
IP  - 8
DP  - 2014
TI  - Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma.
PG  - 5045-50
AB  - BACKGROUND: Most Hodgkin lymphoma (HL) patients present with disease in nodal 
      regions. However, in a small subset, disease develops extranodal sites primarily, 
      such as lung and liver. This study aims to identify the characteristics and 
      outcomes of patients with primary extranodal HL. METHODS: A retrospective 
      analysis of patients with HL from 1998 to 2012 was enrolled. We selected 26 HL 
      patients with primary extranodal involvement from 251 previously untreated HL 
      patients. All data analyses were performed with SPSS software version 17.0 and 
      GraphPad Prism 5. RESULTS: We identified 26 patients with primary extranodal HL. 
      Results in the series of young patients, male predominated. Pathologically, the 
      major pathologic types were nodular sclerosis classical HL (NSCHL, 46.2%) and 
      mixed cellularity classical HL (MCCHL, 38.5%). Thirteen patients had early stage 
      (I or II stage). The most commonly primarily extranodal sites were the lung and 
      the stomach and intestine, followed by the liver and bones. Fifteen of 26 
      received chemotherapy alone and 11 received combination therapy. Finally, primary 
      extranodal HLs in our study have a favorable survival. Furthermore, there was no 
      significant association between the international prognostic score (IPS) and 
      survival in patients with extranodal HL. CONCLUSION: Our retrospective data in 
      part reflect clinical characteristics of primary extranodal HL in China, and form 
      the basis for further concerning researches.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Wang, Yafei
AU  - Wang Y
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Zhao, Haifeng
AU  - Zhao H
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Liu, Su
AU  - Liu S
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Lin, Li
AU  - Lin L
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Yue, Yuanfang
AU  - Yue Y
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Wang, Xiaofang
AU  - Wang X
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Yu, Yong
AU  - Yu Y
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
FAU - Zhang, Yizhuo
AU  - Zhang Y
AD  - Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, 
      Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
LA  - eng
PT  - Journal Article
DEP - 20140715
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Neoplasms/mortality/pathology/therapy
MH  - Chemoradiotherapy
MH  - Disease-Free Survival
MH  - Female
MH  - Gastrointestinal Neoplasms/mortality/pathology/therapy
MH  - Hodgkin Disease/*mortality/*pathology/*therapy
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/mortality/pathology/therapy
MH  - Male
MH  - Proportional Hazards Models
MH  - Retrospective Studies
PMC - PMC4152067
OTO - NOTNLM
OT  - 18F-FDGPET-CT
OT  - Hodgkin's lymphoma
OT  - extranodal
OT  - international prognostic score
OT  - prognosis
OT  - survival
EDAT- 2014/09/10 06:00
MHDA- 2015/06/10 06:00
PMCR- 2014/07/15
CRDT- 2014/09/09 06:00
PHST- 2014/05/29 00:00 [received]
PHST- 2014/07/12 00:00 [accepted]
PHST- 2014/09/09 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/06/10 06:00 [medline]
PHST- 2014/07/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2014 Jul 15;7(8):5045-50. eCollection 2014.